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ABSTRACT
Introduction To investigate the effect of an exercise 
prescription and a 1- year supervised exercise intervention, 
and the modifying effect of the family history of type 2 
diabetes (FH), on long- term cardiometabolic health.
Research design and methods For this prospective 
randomized trial, we recruited non- diabetic participants 
with poor fitness (n=1072, 30–70 years). Participants were 
randomly assigned with stratification for FH either in the 
exercise prescription group (PG, n=144) or the supervised 
exercise group (EG, n=146) group and compared with a 
matched control group from the same population study (CON, 
n=782). The PG and EG received exercise prescriptions. In 
addition, the EG attended supervised exercise sessions two 
times a week for 60 min for 12 months. Cardiometabolic risk 
factors were measured at baseline, 1 year, 5 years, and 6 years. 
The CON group received no intervention and was measured at 
baseline and 6 years.
Results The EG reduced their body weight, waist 
circumference, diastolic blood pressure, and low- density 
lipoprotein- cholesterol (LDL- C) but not physical fitness 
(p=0.074) or insulin or glucose regulation (p>0.1) compared 
with the PG at 1 year and 5 years (p≤0.011). The observed 
differences were attenuated at 6 years; however, participants 
in the both intervention groups significantly improved their 
blood pressure, high- density lipoprotein- cholesterol, and insulin 
sensitivity compared with the population controls (p≤0.003). FH 
modified LDL- C and waist circumference responses to exercise 
at 1 year and 5 years.
Conclusions Low- cost physical activity programs have 
long- term beneficial effects on cardiometabolic health 
regardless of the FH of diabetes. Given the feasibility and 
low cost of these programs, they should be advocated to 
promote cardiometabolic health.
Trial registration number  ClinicalTrials. gov identifier 
NCT02131701.
INTRODUCTION
Regular physical activity has been asso-
ciated with a myriad of health benefits 
including reduced risk of mortality, diabetes 
and other non- communicable diseases.1–5 
Exercise interventions can also positively 
affect cardiometabolic health by improving 
maximum oxygen uptake (VO2max), insulin 
sensitivity, adiposity, LDL- cholesterol (LDL- 
C), and blood pressure.6–8
Although physical activity has a central 
role in the prevention and treatment of type 
2 diabetes, the interindividual variability in 
response to exercise is large.9 10 Heterogeneity 
Significance of this study
What is already known about this subject?
 ► Family history of type 2 diabetes is associated with 
reduced physical fitness and a lower expression of 
genes in the oxidative phosphorylation.
 ► Limited prospective data are available on how type 2 
diabetes or family history of type 2 diabetes affects 
physical fitness or metabolic response to exercise.
What are the new findings?
 ► Family history of type 2 diabetes attenuated the 
effect of exercise on waist circumference and low- 
density lipoprotein.
 ► One- year low- cost structured exercise intervention 
and exercise prescription intervention similarly led 
to an improved cardiometabolic health 6 years later 
compared with the population- based control group.
How might these results change the focus of 
research or clinical practice?
 ► Individuals with family history of type 2 diabetes 
can in most parts expect similar cardiometabol-
ic health benefits from regular exercise; however, 
the diminished responsiveness to waist circumfer-
ence and low- density lipoprotein warrants further 
investigation.
 ► Physical activity prescription could be a feasible and 
readily available option to promote long- term car-
diometabolic health in low fit populations.
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in VO2max training response is strongly explained by heri-
tability (47%), but only minimally by age, sex, and ethnic 
origin.10 11 A genetic component is supported by reports of 
reduced physical fitness and a lower expression of genes 
in the oxidative phosphorylation pathway in patients with 
type 2 diabetes and their family members.12–15 Family 
history of type 2 diabetes (FH) could also limit muscle 
adaptation to exercise and possible health benefits.16 
However, only few prospective studies have investigated 
the influence of type 2 diabetes or FH on the metabolic 
response to exercise.16 17
Therefore, this study aimed to investigate the long- 
term (5 years) effect of exercise prescription versus a 
1- year supervised exercise intervention (EG) on aerobic 
physical fitness, muscle strength, and cardiometabolic 
parameters in subjects with poor physical fitness, strati-
fied for FH. We also compared the change in measured 
outcomes between the intervention groups and matched 
control subjects originating from the same population 
study at 6 years.
RESEARCH DESIGN AND METHODS
Study participants
The Prevalence, Prediction and Prevention of diabetes 
(PPP)- Botnia Study is a population- based study (n=5 208) 
in Western Finland initiated to obtain accurate estimates 
of prevalence and risk factors for diabetes, pre- diabetes 
and the metabolic syndrome in the adult population and 
to use this information for prediction and prevention of 
the disease.12 The baseline study was conducted in 2004–
2008 and the prospective study in 2010–2015.18 For the 
present randomized parallel group clinical trial (RCT, 
ClinicalTrials. gov identifier NCT02131701) we recruited 
consecutive male and female participants from the PPP- 
Botnia Study who fulfilled the following criteria: (1) no 
diabetes and aged 30–70 years ; (2) poor physical fitness 
based on a 2 km walking test (fitness index <90); and (3) 
no contraindications for physical training based on a phys-
ical examination including ECG. Of the 507 consecutive 
eligible participants invited, 290 gave written informed 
consent. Included participants were randomized (1:1) 
in four blocks to an exercise group (EG) (n=146) and a 
prescription group (PG) (n=144) based on gender and 
FH, which was defined as one first- degree or two second- 
degree relatives with type 2 diabetes. The basal visit took 
place between October 2006 and August 2008. The 1- year 
follow- up study was performed in 2007–2009, and the 
5- year follow- up was performed between 2011 and 2013. 
Participants or care providers were not blinded, as this 
is rather impossible. However, those assessing outcomes 
were blinded for allocation. All participants gave written 
informed consent before taking part to the study.
In addition to the exercise intervention groups, a 
population- based control group (CON; n=782) was 
recruited from the participants in the PPP- Botnia Study. 
The CON group received no specific intervention. Male 
and female participants were considered eligible for the 
CON group if they were (1) non- diabetic and aged 30–70 
years, (2) had poor physical fitness based on a 2 km 
walking test (fitness index <90 in two walking tests) and 
(3) participated in both the baseline and 6- year follow- up 
study. The CON group was subdivided according to the 
FH by same criteria as the intervention groups. The base-
line visits occurred 2004–2008 and 6- year follow- up visits 
2010–2015. The online supplemental figure S1 describes 
the flow of the study.
Interventions
All study subjects participated in two individual sessions 
of exercise prescription aiming at 30 min of moderate 
exercise at least 5 days a week. They also received exercise 
diaries. Participants in the PG performed unsupervised 
training, while participants in the EG were offered super-
vised physical training in groups twice a week during 12 
months. The supervised training included both endur-
ance training (Nordic walking and water gymnastics) 
and resistance training in a gym. The training sessions 
lasted 60 min including warm- up. To control the intensity 
of aerobic training, 70%–85% of age- adjusted maximal 
pulse rate was recommended, and heart rate moni-
toring was used periodically. Muscle strength training 
was performed in two sets of 12–15 repetitions focusing 
on major muscle groups. The first set (warm- up) was 
performed with 10 repetitions at 50% of repetition 
maximum, and the second set at 70%. Resistance was 
progressively increased according to the repeated testing 
of muscle strength. Experienced trainer supervised the 
training and also performed the testing of the muscle 
strength.
Timing of the measurements
In the PG and EG, all measurements were taken at base-
line, 1 year, and 5 years. All measurements were also 
collected from the CON group at baseline. At 6- year 
follow- up, body composition, waist circumference, blood 
pressure, blood lipid and glucose metabolism were 
measured from all groups (PG, EG, and CON).
Assessment of aerobic physical fitness, steps, and muscle 
strength
Aerobic physical fitness as a primary outcome was 
assessed in all subjects by a 2 km walking test (UKK), 
which provides an indirect estimate of oxygen uptake.19 20 
Based on walking time and heart rate at the end of the 
test, a fitness index (<70: very poor, 70–89: poor, 90–110: 
normal, 111–130: good, and >130: very good) adjusted 
for age, gender and body mass index (BMI) was calcu-
lated. The repeated tests were performed on the same 
track and at the same time of the year. At baseline, the 
number of steps per day was measured with Actiheart 4 
(CamNtech Ltd. UK).
Muscle strength (arm push, arm pull, leg extension 
and leg flexion) was assessed by fitness equipment (Ab 
Hur Oy, Finland) after a 5–10 min warm- up. Each subject 
performed five repetitions during 10 s. The resistance 
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was increased until the subjects were unable to perform 
more. One repetition maximum (1 RM) was calculated 
based on the Brzyckis formula: 1 RM = weight/(1.0278 – 
(0.0278 × repetitions)).21 Assessment of muscle strength 
was carried out on all participants in the training group 
and in a subgroup of consecutive participants in the 
prescription- of- exercise group. Number of subjects who 
participated in muscle strength testing at baseline was 
135 subjects (EG: n=106, PG: n=29), at 1 year 128 subjects 
(n=100 and n=28, respectively) and at 5 years 136 subjects 
(n=108 and n=28, respectively).
Anthropometrics and blood pressure
Body weight (Tanita BF-350, Japan) and height were 
measured with subjects in light clothing without shoes, 
and BMI was calculated. Waist circumference was 
measured with a soft tape on standing subjects midway 
between the lowest rib and the iliac crest. Two blood pres-
sure recordings (Omron 711) were obtained from the 
right arm of a sitting person after 30 min of rest at 5 min 
intervals, and their mean value was calculated.
Questionnaires and diaries
Questionnaires were used to obtain information about 
other diseases, current medication, smoking and alcohol 
consumption. At baseline, 1 year and 5 year follow- up 
frequency and intensity of physical activity during the past 
12 months was assessed using the validated Kuopio Isch-
emic Heart Disease questionnaire (KIHD).22 It provides 
detailed information on common lifestyle, commuting 
and leisure time physical activity and enables assessment 
of physical activity as metabolic equivalent of task (MET) 
hours per week (MET- hour/week). Furthermore, during 
the 1- year intervention, all participants in the PG and 
EG kept an exercise diary, in which they were instructed 
to log every exercise that they performed during the 
1- year period. The activities were then transformed to 
MET- hours per week and categorized into aerobic, gym 
or resistance training type of exercises and other miscel-
laneous physical activities. Miscellaneous physical activi-
ties included non- exercise type of activities, for example, 
home activities, home repair, lawn moving and gardening 
activities. In addition to the exercise diary, participants in 
the EG were instructed to log every supervised exercise 
session, including type, duration, and frequency. They 
performed three types of exercise (resistance training, 
Nordic walking, or aquatic training). The physical dose 
(duration, frequency, intensity, and volume) of the 
training was calculated. For each type of supervised exer-
cise, a MET- value was calculated based on the Compen-
dium of Physical Activities.23 The time- weighted average 
intensity of the training was expressed in MET- values 
and volume in MET- hours.24 Information on possible 
adverse effects was collected based on the participants 
reporting during the intervention. A questionnaire was 
also used collect data on type blood pressure, cholesterol, 
and diabetes medication at baseline and at 6 years. The 
information of each medication was dichtomized (0=no 
and 1=yes).
Analytical measurements
The subjects participated in an oral glucose tolerance test 
(OGTT) by ingesting 75 g of glucose (Glucodyn, Leiras, 
Turku, Finland) after a 12- hour overnight fast. Samples 
for the measurement of plasma glucose and serum 
insulin were drawn at 0, 30, and 120 min. Glucose and 
insulin area under curve (AUC glucose; AUC insulin=15 
× fasting concentration+60 × concentration at 30 min+45 
× concentration at 120 min) were also calculated. Fasting 
samples were drawn for the measurement of serum total 
cholesterol, high- density lipoprotein cholesterol (HDL- 
C), and triglyceride concentrations. LDL- C concentra-
tions were calculated using the Friedewald formula.25
Serum insulin concentrations were measured with a 
fluorometric immunoassay (AutoDELFIA B080-101- assay, 
PerkinElmer, USA), plasma glucose by HemoCue Glucose 
201- assay (HemoCue, Sweden), and serum lipids by an 
immunoturbidometric method (Konelab 60i 981700, 
Thermo Fisher Scientific, USA). Insulin sensitivity was 
assessed with homeostasis model assessment for insulin 
resistance (HOMA- IR=[(fasting serum insulin concen-
tration/fasting plasma glucose concentration)/22.5]26 
and with insulin sensitivity index (ISI=10 000/√(fasting 
glucose × fasting insulin × mean OGTT glucose × mean 
OGTT insulin)). As indices of insulin secretion, we used 
corrected insulin response (CIR=(100×insulin at 30 
min)/((glucose at 30 min)×(glucose at 30 min–3.89))) 
and disposition index (DI=CIR×ISI).
Statistical analyses
According to power analysis, 71 participants in each 
group were required to detect (power 80% and 95% CI) 
a 20% difference between the groups in achieving a 15% 
improvement in physical fitness. All data are reported as 
mean (SD or 95% CIs).
General linear models were used to compare the base-
line characteristics between the groups (EG and PG strat-
ified for FH). Linear mixed models were applied to test 
the differences between the PG and the EG during the 
1- year and 5- year follow- up. The independent variables 
for these models were group (EG vs PG), time (baseline, 
1 year, and 5 years), and FH and their interaction (group 
× time × FH). This model was employed to test the impact 
of FH on exercise responses (group × time × FH interac-
tion effect) and the differences between the EG and PG 
(time × group interaction effect). Subjects who had data 
on all time- points for a specific variable were included in 
the analyses. Nominal p values are reported, and alpha 
level 0.05 was set as a threshold for statistical significance. 
Pearson correlation was used to measure correlation 
between the exercise dose during the 1- year intervention 
and the residual change in outcomes from baseline to 1 
year.
The marginal mean weighting through stratification 
(MMWS) method was applied to estimate the average 
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treatment effect between the intervention groups (PG 
and EG) and the CON group.27–30 MMWS incorporates 
two propensity score based techniques (stratification and 
weighting) to reweight the dataset. The propensity score 
for each treatment group was estimated with multinomial 
logistic regression, where treatment allocation (PG, EG, 
and CON) was explained by the pretreatment covariates 
(sex, age, BMI, follow- up time, and fitness index). Each 
of the three propensity scores was then stratified into 
tertiles to reduce the initial bias in the covariates.31 The 
generated weights were then incorporated in the regres-
sion model.
The 6- year response was compared between groups 
with and without FH and adjusted for baseline values. 
To correct for multiple comparisons (PG vs CON, EG vs 
CON, PG vs EG, and PG+EG vs CON), a p value <0.0125 
(=0.05/4=0.0125) was used as a threshold for statistical 
significance in these analyses.
The generalized estimating equations were applied to 
compare the change in usage of medication for blood 
pressure and cholesterol between the CON, PG, and EG 
from baseline to 6- year follow- up. Penalized maximum 
likelihood logistic regression (Firth’s logistic regression) 
was used to compare the diabetes medication between 
the groups at 6 years, as none of the participants had 
diabetes medication at baseline, and the frequencies 
were low at 6 years.
All analyses were performed with Stata/SE V.14.2, 
Stata/MP V.15.1, and Stata/MP V.16.1.
RESULTS
Baseline characteristics of the intervention groups
A total of 290 participants were randomized into the two 
intervention arms. Altogether 266 participants (136 in 
PG and 130 in EG), who completed the 5- year follow- up, 
were included in the primary analyses (online supple-
mental figure S2). Baseline characteristics between the 
intervention groups stratified for FH were similar expect 
for LDL- C (table 1). LDL- C was 0.4 mmol/L (95% CI 
0.1 to 0.7) higher in the FH individuals in the exercise 
intervention compared with the FH individuals in the 
prescription group. No other significant differences were 
detected between the intervention groups.
Attendance for interventions and physical activity
During the 1- year intervention, 44% of the participants 
in the EG trained on average at least once and 11% 
trained at least twice per week. No significant differences 
in the dose of the intervention was observed between the 
FH− and FH+ groups (p>0.1) (online supplemental table 
S1). According to the exercise diaries, during the 1- year 
intervention, the EG performed on average more gym or 
resistance training type of exercise than the PG (online 
supplemental table S2). No significant differences were 
detected in aerobic type of exercises, miscellaneous 
physical activities or in total physical activity during the 
1- year period. Also, we detected no significant between 
the group differences in volume of leisure time phys-
ical activity at baseline, 1 year or 5 years measured with 
12- month KIHD recall questionnaire (online supple-
mental table S3).
The influence of mode of intervention exercise response at 1 
and 5 years
The EG had significantly lower body weight and waist 
circumference at 1 year, as well as lower total cholesterol, 
LDL- C, and diastolic BP (table 2) and better muscle 
strength (online supplemental table S3) at both 1 and 5 
years compared with the PG (p≤0.019). Overall, however, 
the beneficial metabolic changes obtained at the 1- year 
follow- up in the intervention groups tended to fade at 
5 years. No other significant differences were detected 
(online supplemental table S3). The sensitivity analyses 
for the main outcomes described in online supplemental 
table S6 indicated that these findings remained similar, 
even when we included all the participants in the anal-
yses that had data on at least from one time- point (base-
line, 1 year and 5 years). In addition, results remained 
similar when models were adjusted for baseline physical 
activity, physical activity by time interaction or volume 
of resistance training (data not shown). The correlation 
coefficients between the volume of exercise performed 
during the 1- year intervention and the residual change 
in outcomes from baseline to 1 year are described in the 
heat map in the online supplemental figure S3. There 
were no reported adverse effects in either group.
Exercise interventions versus population-based controls at 6 
years
At 6 years (median=6.7 years, IQR=0.9), there were no 
significant differences between the PG and EG in change 
any of the outcomes (p>0.079) (online supplemental 
table S4), which is why we investigated contrast between 
the pooled intervention group (PG+EG) and the CON 
group. To compare effects of intervention with the status 
of the general population, we compared 275 randomized 
participants (PG+EG) and 782 matched control subjects 
(CON) who had participated in the 6- year prospective 
part of the PPP- Botnia Study (online supplemental figure 
S2).
The baseline characteristics were similar between the 
CON and the pooled intervention group, except for 0.1 
mm Hg (95% CI 0.04 to 0.2) lower fasting glucose, 2.6 
mmol/L (95% CI 1.3 to 4.0) lower diastolic blood pres-
sure, and 8.1 IU/L (95% CI 2.3 to 13.8) higher 30 min 
insulin level in the pooled intervention compared with 
the CON group (table 3, online supplemental table S5).
Compared with CON group, the pooled intervention 
group had significantly lower systolic and diastolic blood 
pressure, insulin levels, HOMA- IR, and higher HDL- C 
at 6 years (table 3) and a nominally significant decrease 
in 2- hour glucose from the baseline. The intervention 
groups also showed a slightly higher increase in fasting 
glucose from baseline compared with the CON group, 
which could possibly be explained by the lower fasting 
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glucose in the pooled intervention group at baseline 
(online supplemental table S5). The usage of blood 
pressure, cholesterol and diabetes medication increased 
similarly in each group during the 6- year period (online 
supplemental figure S4).
The influence of FH on exercise response
FH modified the response of lipids and waist circumfer-
ence to training. In FH− individuals, EG improved LDL- C 
at both 1 and 5 years and waist circumference at 1 year 
compared with the PG (figure 1C and E). No such effects 
were found in the FH+ group, which showed similar 
response to EG and PG interventions (figure 1D and F). 
At 1 year and 5 years, FH did not significantly influence 
the exercise response measured as aerobic fitness (p for 
time × group × FH interaction=0.11) (figure 1A and B) or 
any other outcomes.
At 6 years, there was a significant interaction between 
the mode of intervention (EG and PG) and FH on the 
change in LDL- C (group × FH interaction effect) (online 
supplemental figure S5). Among the FH− group, LDL- C 
decreased in the EG compared with the PG (p=0.023), 
but no such effect was detected among the FH+ group 
Table 1 Baseline characteristics of individuals in the intervention groups stratified for family history of type 2 diabetes (FH)
Variable
Prescription group (PG) Exercise group (EG)
P value
FH− (n=71) FH+ (n=73) FH− (n=72) FH+ (n=74)
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
Males, n (%) 71 39 (55) 73 35 (48) 72 42 (58) 74 36 (48) 0.535
Age (years) 71 49.1 (12) 73 50.9 (10.6) 72 49.6 (11.8) 74 49.2 (10.6) 0.769
Weight (kg) 66 81.7 (13.2) 68 81.1 (14.8) 62 83.5 (14.5) 65 82.8 (15.3) 0.781
BMI (kg/m2) 71 27.5 (3.2) 71 28.2 (3.7) 72 28.2 (4.3) 74 28.1 (4.0) 0.643
BMI categories, n(%) 0.861
  Normal weight (<25 kg/m2) 71 12 (17) 71 12 (17)) 72 15 (21) 74 13 (18)
  Overweight (25–29.9 kg/m2) 71 45 (63) 71 39 (55) 72 40 (56) 74 40 (54)
  Obese (≥30 kg/m2) 71 14 (20) 71 20 (28) 72 17 (24) 74 21 (28)
Waist circumference (cm) 66 95 (11.1) 68 93.4 (11.8) 62 97.2 (13.6) 65 95.3 (12.9) 0.379
Fitness index 71 73.8 (12.1) 73 73.3 (15.6) 72 72.2 (18.5) 74 73.1 (15) 0.932
LTPA (met- hours/week) 66 19 (20.2) 69 22.8 (22.7) 63 25.1 (22.8) 64 26 (19.9) 0.256
Number of steps 52 6.4 (2.5) 62 6.7 (2.5) 46 6.5 (2.4) 53 6.5 (2.9) 0.958
Blood pressure medication, n(%) 71 6 (13) 73 17 (23) 72 14 (19) 74 12 (16) 0.395
Lipid medication, n(%) 71 6 (8) 73 4 (5) 72 10 (14) 74 7 (9) 0.394
Systolic BP (mm Hg) 66 134.1 (15.3) 68 136.7 (14.5) 62 134.8 (15.4) 65 132.6 (14.4) 0.459
Diastolic BP (mm Hg) 71 82.6 (8.7) 73 81.4 (8.4) 72 82.7 (8.9) 74 82 (8.8) 0.804
Triglycerides (mmol/L) 71 1.23 (0.62) 73 1.27 (0.58) 72 1.37 (0.81) 74 1.39 (0.74) 0.437
Total cholesterol (mmol/L) 71 5.07 (0.88) 73 5.36 (0.9) 72 5.46 (0.9) 74 5.28 (1.06) 0.085
HDL cholesterol (mmol/L) 71 1.4 (0.43) 73 1.41 (0.41) 72 1.34 (0.39) 74 1.34 (0.38) 0.593
LDL cholesterol (mmol/L) 71 3.11 (0.8) 73 3.37 (0.85 69 3.51 (0.77) 72 3.31 (0.91) 0.039
Fasting glucose (mmol/L) 71 5.4 (0.5) 73 5.5 (0.6) 72 5.4 (0.5) 73 5.5 (0.5) 0.061
30 min glucose (mmol/L) 70 8.1 (1.6) 73 8.4 (1.5) 72 8 (1.5) 73 8.6 (1.7) 0.142
2- hour glucose (mmol/L) 71 5.2 (1.5) 73 5.4 (1.4) 72 5.1 (1.3) 73 5.4 (1.5) 0.641
AUC glucose 70 861.7 (139.1) 73 887.7 (127.2) 72 853.2 (119.9) 73 901 (145.7) 0.112
Fasting insulin (mU/L) 68 7.4 (7.3) 73 6.6 (3.7) 68 6.9 (4.5) 66 7.3 (4.7) 0.755
30 min insulin (mU/L) 67 63.4 (34.4) 72 61.5 (37.1) 68 65.4 (37) 66 70.6 (42.1) 0.529
2- hour insulin (mU/L) 68 32.4 (29.8) 70 31.1 (22.9) 68 31.4 (23.3) 65 32.3 (24.5) 0.986
AUC insulin (103) 67 5.43 (2.94) 70 5.28 (2.92) 68 5.5 (3) 65 5.9 (3.16) 0.678
ISI 67 156.9 (87.8) 70 148 (69.5) 68 147.4 (76.9) 65 138.7 (86) 0.638
CIR 67 240.2 (289.8) 72 181.2 (111.5) 68 224.4 (171.1) 66 251.6 (356.1) 0.359
DI (103) 67 34.2 (41.2) 70 25.7 (17.8) 68 31.5 (31.7) 65 29 (35.2) 0.474
HOMA- IR 69 1.8 (2.0) 71 1.6 (1.0) 67 1.7 (1.1) 66 1.8 (1.2) 0.750
Data are shown as mean (SD) unless otherwise stated.
AUC, area under the curve; BMI, body mass index; BP, blood pressure; CIR, corrected insulin response; DI, disposition index; FH, family history of 
type 2 diabetes; HDL, high- density lipoprotein; HOMA- IR, homeostasis model assessment for insulin resistance; ISI, insulin sensitivity index; LDL, 
low- density lipoprotein; LTPA, leisure time physical activity.
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Table 2 The comparison of the effect of 1- year prescription- only intervention and supervised exercise intervention on 
physical fitness, body weight, waist circumference, blood pressure, lipid and glucose metabolism at 1 year and 5 years
Variable N
Mean (SE)
Exercise versus prescription group change
P for time × 
group interaction
Mean (95% CI)*
Baseline 1 year 5 years 1 year 5 years
Fitness index
  Prescription 99 74.2 (1.2) 83.1 (83.1) 81.5 (1.6)
  Exercise 94 73.7 (1.4) 84.3 (84.3) 79.3 (1.8) 1.7 (−1.1 to 4.5) −1.6 (−5.0 to 1.8) 0.074
Weight (kg)
  Prescription 134 81.4 (1.2) 81.1 (81.1) 82.0 (1.3)
  Exercise 127 83.2 (1.3) 81.9 (81.9) 84.2 (1.4) −0.9 (−1.7 to −0.2) 0.4 (−0.7 to 1.5) 0.008
Waist circumference (cm)
  Prescription 134 94.2 (1.0) 92.3 (92.3) 94.9 (1.0)
  Exercise 127 96.2 (1.2) 93.2 (93.2) 97.4 (1.1) −1.3 (−2.4 to −0.1) 0.5 (−0.9 to 1.8) 0.011
Systolic BP (mm Hg)
  Prescription 132 135.2 (1.3) 132.1 (132.1) 134.4 (1.4)
  Exercise 126 133.7 (1.3) 128.5 (128.5) 131.0 (1.4) −2.1 (−4.7 to 0.5) −1.9 (−4.9 to 1.2) 0.244
Diastolic BP (mm Hg)
  Prescription 132 81.9 (0.8) 78.8 (78.8) 76.0 (0.8)
  Exercise 126 82.6 (0.8) 77.9 (77.9) 74.2 (0.7) −1.6 (−3.2 to −0.04) −2.5 (−4.3 to −0.6) 0.019
Triglycerides (mmol/L)
  Prescription 136 1.27 (0.05) 1.27 (1.27) 1.32 (0.06)
  Exercise 128 1.4 (0.07) 1.25 (1.25) 1.44 (0.07) −0.15 (−0.31 to 0.01) −0.01 (−0.15 to 0.13) 0.147
Total cholesterol (mmol/L)
  Prescription 136 5.26 (0.08) 5.35 (5.35) 5.68 (0.09)
  Exercise 128 5.36 (0.09) 5.24 (5.24) 5.46 (0.09) −0.21 (−0.41 to −0.01) −0.32 (−0.52 to −0.12) 0.006
HDL- cholesterol (mmol/L)
  Prescription 136 1.40 (0.04) 1.47 (1.47) 1.42 (0.04)
  Exercise 128 1.35 (0.03) 1.41 (1.41) 1.32 (0.04) −0.01 (−0.08 to 0.05) −0.05 (−0.11 to 0.01) 0.210
LDL- cholesterol (mmol/L)
  Prescription 132 3.25 (0.07) 3.29 (3.29) 3.64 (0.08)
  Exercise 121 3.38 (0.08) 3.25 (3.25) 3.49 (0.08) −0.17 (−0.35 to 0.004) −0.28 (−0.46 to −0.10) 0.006
Fasting glucose (mmol/L)
  Prescription 135 5.4 (0.05) 5.3 (5.3) 5.5 (0.05)
  Exercise 129 5.5 (0.04) 5.4 (5.4) 5.6 (0.1) 0.0 (−0.1 to 0.1) 0.03 (−0.1 to 0.2) 0.831
30 min glucose (mmol/L)
  Prescription 131 8.3 (0.1) 8.2 (8.2) 8.5 (0.1)
  Exercise 123 8.4 (0.1) 8.3 (8.3) 8.8 (0.2) 0.03 (−0.3 to 0.4) 0.3 (−0.1 to 0.6) 0.307
2- hour glucose (mmol/L)
  Prescription 132 5.3 (0.1) 5.1 (5.1) 5.4 (0.1)
  Exercise 125 5.2 (0.1) 4.8 (4.8) 5.5 (0.1) −0.2 (−0.6 to 0.1) 0.1 (−0.3 to 0.5) 0.123
Fasting insulin (mU/L)
  Prescription 130 7.1 (0.5) 6.1 (6.1) 7.3 (0.4)
  Exercise 126 7.2 (0.4) 6.7 (6.7) 8.4 (0.5) 0.4 (−0.7 to 1.6) 1 (−0.2 to 2.3) 0.231
30 min insulin (mU/L)
  Prescription 125 63.4 (3.2) 62.0 (62.0) 68.3 (3.8)
  Exercise 120 68.1 (3.7) 60.9 (60.9) 75.6 (4.9) −5.8 (−13.4 to 1.8) 2.6 (−7.1 to 12.4) 0.202
2- hour insulin (mU/L)
  Prescription 124 32.3 (2.1) 27.9 (27.9) 36.2 (2.8)
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(p=0.815). However, among the FH+, both intervention 
groups had a similar increase in their LDL- C compared 
with the CON group, but this was statistically significant 
only for the PG (p=0.023). No other significant group × 
FH+ interactions were found (p>0.07). No other signif-
icant group × FH+ interactions were found (p>0.07) 
(table 3).
DISCUSSION
In an adult non- diabetic population with low cardiorespi-
ratory fitness, we detected no difference in cardiorespi-
ratory fitness between the 1 year EG or PG interventions 
at 1 or 5 years. The 1- year EG intervention, however, 
induced greater improvement in muscle strength, larger 
reduction in body weight and diastolic blood pressure, 
and LDL- cholesterol than the prescription only interven-
tion. In addition, contrary to our hypothesis, we found 
no strong evidence that FH modifies individual respon-
siveness to exercise. Our findings suggest that individuals 
with FH may be less prone to reduce their LDL- C and 
possibly waist circumference with exercise, but overall, 
they achieve similar exercise- induced improvements in 
insulin resistance, HDL- C, and blood pressure as individ-
uals without FH. The main finding was that irrespective 
of the mode of intervention, the 1- year low- cost exer-
cise interventions resulted in a lower 6- year systolic and 
diastolic blood pressure, insulin levels, HOMA- IR and 
higher HDL- C compared with the background popula-
tion, the CON group, taken from the same population 
study. Thus, the present findings support the conclusion 
that both EG and PG interventions have beneficial long- 
term effects on cardiometabolic health independent of 
the FH status.
The strength of the study is the population- based 
recruitment of the study participants and random allo-
cation of participants into a training and prescription 
group. We also observed a very low overall dropout rate, 
as 91.7% of the participants participated in the 5- year 
examination. We were able to take a real- life control 
group from the PPP- Botnia cohort and to estimate the 
propensity score based average treatment effect of those 
who did or did not receive the intervention. Furthermore, 
participants reported no major adverse effects that can 
be traced back to the interventions. Thus, these interven-
tions can be safely recommended for adult populations.
There are some limitations of the current study 
that should be addressed. As in many other studies, 
we encountered problems with monitoring physical 
activity and quantity and intensity of exercise interven-
tions. The key instruments were 12- month recall ques-
tionnaire, the exercise diary and adherence to weekly 
exercise sessions, but this was left to the individual’s 
compliance. Although we aimed to test a less resource- 
consuming intervention, in future studies, it may be 
beneficial to include activating contacts, including 
new web- based technologies, by health professionals or 
trainers to increase the motivation and adherence to 
the intervention.
In the present study, individually given low- resource 
intensive exercise prescription intervention aiming for 
150 min of exercise per week provided similar long- term 
cardiometabolic health benefits as the supervised exer-
cise intervention in low- risk population. Participants that 
received either type of exercise intervention (PG+EG) 
improved their blood pressure, HDL- C, and insulin sensi-
tivity, without a significant change in the waist circum-
ference or body weight, compared with the CON group 
during the 6.8- year follow- up (table 3). Our findings 
support the findings from previous studies reporting 
beneficial cardiometabolic effects from unsupervised 
or counselling- based exercise interventions.32–34 These 
studies have, however, had relatively short follow- up time 
(6–12 months) and included mostly high- risk popula-
tions. According to the recent review including people 
with no cardiovascular disease risk factors, lifestyle 
interventions (diet and/or exercise) induced a small 
improvement in systolic and diastolic blood pressure, 
LDL- C, BMI, and waist circumference, but not in HDL- 
C.8 In the present study, we observed improvements in 
systolic and diastolic blood pressure, but not in LDL- C 
or in adiposity. However, exercise intervention groups 
improved HDL- C and insulin sensitivity compared with 
the CON group. The discrepancy between the studies is 
most likely explained by the type of intervention, longer 
follow- up, and inclusion of community- based control 
group rather than a randomly allocated control group in 
the present study. Despite small differences between the 
studies, the evidence strongly suggests that low- resource 
intensive exercise intervention is a feasible, low- cost alter-




Exercise versus prescription group change
P for time × 
group interaction
Mean (95% CI)*
Baseline 1 year 5 years 1 year 5 years
  Prescription 126 1.8 (0.1) 1.5 (1.5) 1.8 (0.1)
  Exercise 122 1.8 (0.1) 1.6 (1.6) 2.1 (0.1) 0.1 (−0.2 to 0.5) 0.3 (−0.1 to –0.6) 0.349
*Adjusted for family history of type 2 diabetes.
BP, blood pressure; HDL, high- density lipoprotein; HOMA- IR, homeostasis model assessment for insulin resistance; LDL, low- density lipoprotein.
Table 2 Continued
copyright.
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Both the PG and the EG performed similarly in most 
of the measured variables. The EG gained more muscle 
strength during the intervention, which can be explained 
by the fact that resistance training was the most common 
type of exercise (online supplemental table S1). Also, 
muscle strength measurements were only available from 
a subsample of the PG, which limits the generalizability 
of these findings.
FH did not influence aerobic fitness response to 
training. These findings are consistent with a previous 
study reporting similar increase in the VO2max between 
the first- degree relatives of type 2 diabetic patients 
and controls after a 10- week aerobic exercise interven-
tion.15 Previously, it has also been suggested, although 
informally tested, that FH+ group may require greater 
volume of exercise to achieve similar VO2max gain as the 
FH− group.16 In the present study, such effects were 
unobserved, as the slope between the total volume (MET- 
hours) of exercise and the change in the fitness score 
were similar between the FH− and FH+ groups (p for 
total exercise volume × FH interaction=0.361, data not 








































































































































































































Figure 1 Mean change in fitness index (A and B), LDL- cholesterol (C and D) and waist circumference (E and F) in the 
prescription group (black square) and in the exercise intervention group (white square) in people with (FH+) or without (FH−) 
family history of diabetes. Error bars indicate 95% CI. FH, family history of type 2 diabetes; LDL, low- density lipoprotein.
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likely explained by the differences in the dose (type, 
volume, and intensity) of the exercise interventions and 
that we only included low fit individuals and used indi-
rect measure of physical fitness. Usage of walk test may 
have limited our ability to detect differences between 
the FH− and FH+ groups in fitness. However, in a large 
community- based study, direct measurement of VO2max is 
infeasible. In fact, the walk- test based predicted fitness 
score correlates well with direct VO2 measurements, and 
it can be successfully applied in follow- up studies.19 More-
over, as both intervention groups improved their fitness 
score, the walk test was sensitive enough to capture 
intervention- induced changes in fitness. In addition, a 
previous study that used graded exercise test reported 
similar increases in fitness between the FH− and FH+ 
groups after 8 weeks of training.35 It should, however, be 
emphasized that the observed increase in fitness among 
FH+ does not associate with similar muscle adaptations 
(eg, insulin sensitivity) as in the FH− group.15
Previous studies have well established that regular exer-
cise decreases waist circumference and reduces LDL- C 
level.8 In the present study, such benefits were only 
detected among the FH− group. It has previously been 
reported that FH reduces fat oxidation36 37 and high- fat 
diet induced fat oxidation.38 The reduced fat oxidation 
in response to high- fat diet was unexplained by the differ-
ences in VO2max,
38 which could partly explain why FH 
influenced only on lipoprotein and fat metabolism, but 
not physical fitness. Taken together, we found no strong 
evidence supporting FH as a modifier of cardiometabolic 
response to exercise.
In conclusion, 1- year PG or EG intervention provide 
similar long- term cardiometabolic health benefits 
compared with the community- based control popula-
tion. Although the FH modulated the LDL- C and waist 
circumference response to exercise, it seems that it does 
not systematically modify cardiometabolic response to 
exercise in any major way. These findings illustrate that 
low- resource promotion of physical activity in a clinical 
setting can be a feasible tool for enhancing long- term 
cardiometabolic health in an adult FH− or FH+ popula-
tions. We encourage healthcare policymakers and prac-
titioners to take actions that promote incorporation 
of low- cost physical activity programs into the clinical 
practice.
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